TherapeuticsMD (TXMD) Misses Q3 EPS by 1c

TherapeuticsMD (NASDAQ: TXMD) reported Q3 EPS of ($0.11), $0.01 worse than the analyst estimate of ($0.10). Revenue for the quarter came in at $24.5 million versus the consensus estimate of $25.87 million.

For earnings history and earnings-related data on TherapeuticsMD (TXMD) click here.

You May Also Be Interested In

• Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
• Piper Sandler on Fervo Energy (FRVO): 'Capital Access Supports Potential Upside'
• Goldman "broadly" raises estimates for LTL and truckload stocks